Will DOW disclose a Transform to Outperform run-rate exceeding $1.0B cost savings by Q2 2026 earnings?
Current Prediction
Prediction History
Q1 delivered $193M T2O period cost savings; management reaffirmed $400M H2 run-rate ($1.6B annualized). $1.1B FY26 self-help commitment on track. First site transformation delivered $80M run-rate (exceeded initial projection).
Why This Question Matters
Transform to Outperform is the single most-monitored operational program across four independent lenses. A $1.0B run-rate disclosure by Q2 2026 earnings would confirm execution trajectory toward the $1.5-1.8B realistic delivery range and validate the cycle-recovery framing. A sub-$1B disclosure (or silence on run-rate) would trigger simultaneous downgrades across stress-scanner, roadkill-radar, myth-meter, and moat-mapper assessments. This market directly tests the load-bearing assumption in the thesis.
Prediction Distribution
Individual Predictions(9 runs)
Q1 2026 delivered $193M T2O period cost savings. Management guided H2 2026 to $400M run-rate per quarter = $1.6B annualized. Even at a conservative cumulative cost savings accounting basis (combining remaining 2025 program + T2O productivity), the $1.0B threshold is likely crossed well before Q2 2026 earnings. Management has every incentive to disclose progress in Q2 call to sustain narrative. Probability 0.80.
The question hinges on DISCLOSURE not ACHIEVEMENT. DOW reported $193M Q1 T2O savings explicitly. The Q2 2026 call scheduled late July will include midyear update on Sadara + T2O progress per Fitterling commitment. Cumulative H1 run-rate extrapolation = $193M+$200M = $393M H1, plus $400M/qtr H2 run-rate = $793M 2026 exit run-rate. The $1B threshold depends on whether they report annualized run-rate (likely >$1B by Q2) or cumulative to date (close call). Probability 0.78.
Resolution requires DOW to explicitly cite a cumulative T2O (or successor program) figure exceeding $1.0B. First site transformation delivered $80M run-rate (vs $50M initial projection). Management quantification discipline is improving. But ambiguity exists: DOW reports T2O savings vs remaining 2025 program separately in some venues. If Q2 call cites only T2O (excluding 2025 program), the $1B threshold may not be crossed. Probability 0.76.
Q1 delivered $193M T2O savings. Plus H2 run-rate of $400M/quarter implies $1.6B annualized. By Q2 earnings (late July 2026), DOW will have delivered ~$600M H1 + starting H2 ramp. Management tends to frame aggressive run-rate numbers when transitional metrics cross psychological thresholds. $1B disclosure very likely.
The Q1 2026 call specifically mentioned $193M Q1 savings, $400M run-rate ramp in H2, $400M of $1.3B productivity commitment identified, and $1.1B FY26 total self-help. The $1.0B threshold is on a trajectory to be crossed and disclosed in natural course by Q2 earnings.
Run-rate disclosure likely but $1B threshold specific phrasing matters. Management may cite H2 run-rate (>$1B) OR cumulative savings to date (close to $800M at Q2 call). The binary threshold crossing depends on which metric they emphasize. Leaning YES given momentum.
Q1 T2O savings $193M. H2 run-rate $400M/qtr. Full year self-help $1.1B. $1B disclosure very likely by Q2 call.
Execution on track. Q2 disclosure likely to reference $1B+ run-rate given H2 ramp. Some ambiguity on phrasing.
Q1 delivered against plan; H2 run-rate in guide exceeds $1B annualized. Disclosure threshold very likely crossed.
Resolution Criteria
Resolves YES if DOW discloses a Transform to Outperform (or successor program) cumulative run-rate cost savings / EBITDA uplift figure exceeding $1.0B in a Q1 2026 or Q2 2026 earnings release, earnings call, or 10-Q filed by 2026-08-01. Resolves NO if no such disclosure is made or if the figure is below $1.0B.
Resolution Source
DOW Q1 / Q2 2026 earnings releases, earnings call transcripts, 10-Q filings
Source Trigger
DOW discloses Transform to Outperform run-rate > $1.0B cost savings
Full multi-lens equity analysis